Targets › SIGMAR2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: the race on SIGMAR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | [18F]ISO-1 sigma-2 receptor agonist radiotracer | SIGMAR2 | Phase 1 | Breast Cancer | Nov 2026 |
Breast Cancer (1)
small molecule (1)
University of Pennsylvania (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.